Grifols is a leading global healthcare company. Our trusted and innovative plasma-derived medicines, other biopharmaceuticals and solutions in transfusion medicine enable millions of patients around the world to lead more productive lives.
Grifols is also a leader in transfusion medicine, helping ensure the safety of the world’s blood supply. In addition, we provide biological materials, including plasma, for life-science research and further manufacturing, and the company has a comprehensive portfolio of tools, information and services that enable hospitals to efficiently ...
The Globe and Mail: Health Canada imposes new conditions on Grifols after deaths of two people who donated plasma
Health Canada is imposing new terms and conditions on the licences of Grifols, Canada’s only major commercial collector of blood plasma, after two people died following donations in recent months. The ...
Health Canada imposes new conditions on Grifols after deaths of two people who donated plasma
Two people in Winnipeg have died in recent months after donating blood plasma at collection centres run by Spanish pharmaceutical company Grifols, according to Health Canada. The federal regulator ...
Spanish plasma-derived medicines company Grifols announced that it has successfully completed the refinancing of its 2027 debt maturities through a new credit agreement structured as a Term Loan B ...
Seeking Alpha: Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
The addition of the Clayton site in 2011 marked a new milestone for Grifols (GRFS), turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The ...
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
MSN: Grifols, S.A. (GRFS) to Double Plasma Production With New Spain Facility
Grifols is a global healthcare company that has enhanced the health and well-being of people around the world.
Explore Grifols Poland, a leader in biotechnology and healthcare, dedicated to improving patient lives through innovative therapies and high-quality services.
Descubre las innovadoras soluciones biofarmacéuticas y sanitarias integrales de Grifols centradas en el paciente.
We trace our roots back to 1909 when Dr. Josep Antoni Grifols i Roig founded the first analysis laboratory in Barcelona: Instituto Central de Análisis Clínicos, Bacteriológicos y Químicos.
The sale of a minority stake of its U.S. Biopharma business by means of an initial public offering (IPO) would raise capital to strengthen the Group’s balance sheet, reduce debt and support investment in its strategic growth priorities, while allowing Grifols to maintain majority ownership of its U.S. Biopharma business The proposed transaction reinforces Grifols’ self-sufficiency vision ...
Join Grifols to create a lasting impact with your career. Explore opportunities that allow you to contribute to life-saving solutions and innovate for a healthier future.
Contact Grifols for inquiries and support. Our team is here to assist you with information and resources tailored to your needs.
About Grifols Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. The company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.
The Globe and Mail: Health Canada reviewing deaths of two people who donated plasma at private centres in Winnipeg
Health Canada reviewing deaths of two people who donated plasma at private centres in Winnipeg
Yahoo: Unpacking claim Canada PM Carney tied to sale of donated plasma to foreign company
Add Yahoo as a preferred source to see more of our stories on Google. Getty Images/Snopes Illustration In August 2025, a rumor began to spread that donated blood plasma had been sold for profit to a ...
Unpacking claim Canada PM Carney tied to sale of donated plasma to foreign company
Explore Grifols France for cutting-edge pharmacovigilance and comprehensive medical information to enhance patient safety and treatment outcomes.
P1 is the way Learn to Win can confirm that someone logging in 1) has the appropriate security credentials and 2) is who they say they are. Both of these steps are critical for Learn to Win's ability to host IL4 (CUI) and IL6 (SECRET) level content. Watch this video to learn more about Platform One Onboarding and Registration.
74-2967974 - CSL PLASMA INC. Entity Id: 74-2967974 Type: Foreign Profit Corporation Status: ACTIVE Registration date: 2001 Aug 23 Document Number: F01000004484 Last Event: NAME CHANGE AMENDMENT Event Date Filed: 05/01/2009 Adresses Principal Office Address: 900 Broken Sound Parkway, Ste 400, Boca Raton, FL 33487, changed: 05/30/2020 Mailing Address: 900 Broken Sound Parkway, Ste 400, Boca ...
Hello people! I recently just started donating plasma, great money. I have encountered a problem though, my pulse rate has been too high to give. It
The Globe and Mail: Grifols Refinances 2027 Debt and Extends Maturities with Multi-Billion Term Loan B Package
Detailed price information for Grifols S.A. ADR (GRFS-Q) from The Globe and Mail including charting and trades.
Grifols Refinances 2027 Debt and Extends Maturities with Multi-Billion Term Loan B Package
Yahoo Finance UK: Assessing Grifols (BME:GRF) Valuation After Recent Share Price Weakness And Perceived Discount
Recent performance context for Grifols Grifols (BME:GRF) has drawn investor attention after a mixed run, with a modest 1 day gain, a negative move over the past week and month, and a deeper decline ...
Assessing Grifols (BME:GRF) Valuation After Recent Share Price Weakness And Perceived Discount
The Corner: Grifols plans to make early repayment of €500 million of its 7.5% secured bonds maturing in 2030
Link Securities | Grifols (GRF) plans to make an early repayment of €500 million of its 7.5% senior secured bonds maturing in 2030. This transaction would ...
Grifols plans to make early repayment of €500 million of its 7.5% secured bonds maturing in 2030
Jan 9 (Reuters) - Spanish drugmaker Grifols, whose shares slumped on Tuesday after hedge fund Gotham City Research questioned its accounts, has grown from a family-run blood testing lab founded in ...
Yahoo Finance: Does Grifols (BME:GRF) Offer Opportunity After Sharp Share Price Declines And Debt Concerns
Does Grifols (BME:GRF) Offer Opportunity After Sharp Share Price Declines And Debt Concerns
Grifols (NASDAQ:GRFS) shares shot up by nearly 22% in the premarket session today. The surge followed an approach by its founding family and Brookfield to acquire and delist the Spanish pharmaceutical ...